Cochrane · systematic review · CD013203
Induction immunosuppression in adults undergoing liver transplantation: a network meta‐analysis
Best, LMJ, Leung, J, Freeman, SC, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
26
current version
GRADE rated
23
No studies
3
Included studies
NR
No studies 3 · 11.5%Ungraded 0 · 0%Very low 21 · 80.8%Low 2 · 7.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: adults undergoing liver transplantation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions | no estimate extracted | NR | No studies |
Glucocorticosteroids | no estimate extracted | NR | No studies |
Basiliximab plus glucocorticosteroids (3 RCTs; 627 participants) | HR 0.72 [0.42, 1.15] | NR | Very low Downgraded: risk of bias, imprecision |
Anti‐thymocyte globulin plus glucocorticosteroids (3 RCTs; 152 participants) | HR 1.72 [0.7, 4.28] | NR | Very low Downgraded: risk of bias, imprecision |
Basiliximab (2 RCTs; 131 participants) | HR 0.53 [0.31, 0.93] | NR | Low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (5 RCTs; 1142 participants) | HR 1.33 [0.78, 2.43] | NR | Very low Downgraded: risk of bias, imprecision |
Anti‐thymocyte globulin (2 RCTs; 194 participants) | HR 1.2 [0.58, 2.59] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab (2 RCTs; 350 participants) | HR 1.29 [0.6, 3.06] | NR | Very low Downgraded: risk of bias, imprecision |
No active intervention (1 RCT; 45 participants) | HR 0.75 [0.18, 3.13] | NR | Very low Downgraded: risk of bias, imprecision |
Basiliximab (1 RCT; 47 participants) | HR 0.44 [0.28, 0.7] | NR | Low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (3 RCTs; 927 participants) | HR 1.27 [0.49, 3.75] | NR | Very low Downgraded: risk of bias, imprecision |
Anti‐thymocyte globulin (1 RCT; 119 participants) | HR 0.89 [0.21, 3.88] | NR | Very low Downgraded: risk of bias, imprecision |
No active intervention (only maintenance immunosuppression) (1 RCT; 45 participants) | HR 0.76 [0.12, 4.59] | NR | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life | no estimate extracted | NR | No studies |
Basiliximab plus glucocorticosteroids (2 RCTs; 528 participants) | OR 1 [0.67, 1.47] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) | OR 0.87 [0.65, 1.15] | NR | Very low Downgraded: risk of bias, imprecision |
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37 participants) | Rate ratio 0.63 [0.39, 1.02] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (1 RCT; 148 participants) | Rate ratio 1.12 [0.81, 1.53] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (1 RCT; 698 participants) | HR 1.11 [0.44, 2.78] | NR | Very low Downgraded: risk of bias, imprecision |
Basiliximab plus glucocorticosteroids (1 RCT; 381 participants) | OR 0.98 [0.02, 38.67] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab (1 RCT; 135 participants) | OR 0.27 [0.03, 1.32] | NR | Very low Downgraded: risk of bias, imprecision |
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 93 participants) | Rate ratio 1.3 [0.96, 1.75] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) | HR 1.26 [0.66, 2.42] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab (3 RCTs; 420 participants) | OR 0.62 [0.38, 1.02] | NR | Very low Downgraded: risk of bias, imprecision |
Basiliximab plus glucocorticosteroids (1 RCT; 147 participants) | OR 1.21 [0.52, 2.72] | NR | Very low Downgraded: risk of bias, imprecision |
Daclizumab plus glucocorticosteroids (2 RCTs; 728 participants) | OR 0.94 [0.67, 1.31] | NR | Very low Downgraded: risk of bias, imprecision |